HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitafusion ‘Clinically Proven Absorption’ Claim Fails In C&D Appeal Of Industry Self-Regulation Review

C&D Also Argued NAD Erred In Initial Review Allowing Pharmavite To Expand Challenge

Executive Summary

Church & Dwight will comply with National Advertising Review Board decision to discontinue claim for vitafusion supplements. The panel rejected C&D’s argument that any amount of vitamin absorption is “clinically meaningful” and deferred to the National Advertising Division on C&D’s procedural challenge.

You may also be interested in...

SlimFast ‘Clinically Proven’ Claim Based On Discontinued Products, NAD Review Finds

Glanbia subsidiary marketing SlimFast plans to appeal National Advertising Division decision, following a challenge by Atkins marketer Simply Good, finding a “clinically proven” packaging claim based on evidence from discontinued products isn’t substantiated.

Pharmavite Modifying Claims Challenged In Industry Self-Regulation Rapid Review

In response to Church & Dwight’s Single Well-defined Issue Fast Track challenge at NAD, Pharmavite modifies “clinically proven absorption” claims for Nature Made Multi Complete, Prenatal Multi + DHA Softgels, and Prenatal Gummies by disclosing nutrients clinically tested.

C&D Expands Oral Care Portfolio, Acquires TheraBreath Mouthwash Brand In Latest Deal

Church & Dwight anticipates 15% growth for TheraBreath mouthwash brand in 2022 on larger sizes and wider distribution, especially outside US. It plans to acquire the firm for around $580m cash and close the deal before end of year


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts